Antonio Passaro

European Institute of Oncology — Italy

Medicine · Health Sciences

42h-index8.7kcitations212works27.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(166), Lung Cancer Diagnosis and Treatment(49), Lung Cancer Research Studies(48), Colorectal Cancer Treatments and Studies(43), Cancer Immunotherapy and Biomarkers(34)

Publications210 total

Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact
Journal of Thoracic Oncology·2026· 1 citedOpen Access
A Response to the Letter to the Editor: “Flawed FLAURA Comparisons and Non-Random Biomarker Missingness in US Osimertinib Cohort Study”
Journal of Thoracic Oncology·2025
The risk of lung cancer from vaping or e-cigarette usage: a systematic review
ESMO Open·2025Open Access
Actionable Gene Alterations in Resected Non-Small Cell Lung Cancer: Primary Results From the AGA-R Study
Clinical Lung Cancer·2025· 1 cited
Overall Survival with Amivantamab–Lazertinib in <i>EGFR</i> -Mutated Advanced NSCLC
New England Journal of Medicine·2025· 39 cited
Optimizing management of cutaneous toxicities from amivantamab in first-line non-small cell lung cancer: A clinical perspective
Critical Reviews in Oncology/Hematology·2025· 2 cited
P18-46 Label-free Functional Analysis for the Screening of iPSC-derived Neural Organoid Response to Neuroactive Compounds
Toxicology Letters·2025Open Access
The landscape of conventional and artificial intelligence-based clinical prediction models in non-small-cell lung cancer: from development to real-world validation
ESMO Open·2025· 1 citedOpen Access
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study
European Journal of Cancer·2025· 2 citedOpen Access
Management of MET-Driven Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer
Genes·2025· 4 citedOpen Access
HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs—A Long Way to the Top
Molecules·2025· 10 citedOpen Access
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non–Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab
Journal of Clinical Oncology·2025· 5 citedOpen Access
Patritumab deruxtecan (HER3-DXd) in resistant <i>EGFR</i> -mutated ( <i>EGFR</i> m) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study.
Journal of Clinical Oncology·2025· 18 cited
Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy with or without amivantamab.
Journal of Clinical Oncology·2025
Amivantamab plus chemotherapy vs chemotherapy in <i>EGFR</i> -mutant advanced NSCLC after disease progression on osimertinib: Outcomes by osimertinib resistance mechanisms in MARIPOSA-2.
Journal of Clinical Oncology·2025· 3 cited
SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with <i>HER2</i> -activating mutations.
Journal of Clinical Oncology·2025· 1 cited
Actionable gene alterations in resected non-small cell lung cancer (AGA-R study).
Journal of Clinical Oncology·2025· 1 cited
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)
Annals of Oncology·2025· 24 citedOpen Access
Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) – biology, clinical results and future directions
Cancer Treatment Reviews·2025· 7 cited
Plain language summary of MARIPOSA-2: amivantamab-chemotherapy either with or without lazertinib for treatment of non-small-cell lung cancer
Future Oncology·2025Open Access
page 1 of 11Next →

Frequent Co-authors

Filippo de Marinis(27), Solange Peters(15), Ilaria Attili(13), Enriqueta Felip(9), Gianluca Spitaleri(8), Tony Mok(7), Ester Del Signore(7), Marzia Del Re(7), James Chih‐Hsin Yang(6), Giuseppe Curigliano(6), Umberto Malapelle(6), Jessica Menis(5), Byoung Chul Cho(5), Pongwut Danchaivijitr(5), Sara Pilotto(5), Silvia Novello(5), David Planchard(4), Marcello Tiseo(4), Pasi A. Jänne(4), Nicolas Girard(4)